Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have obtained excellent therapeutic effects against non-small cell lung cancer (NSCLC) harboring activating EGFR mutations. However, some patients have exhibited primary resistance which becomes a major obstacle in effective t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yihan, Pan, Xiaoyan, Xu, Peiqi, Mi, Yanjun, Wang, Wenyi, Wu, Xiaoting, He, Qi, Liu, Xinli, Tang, Weiwei, An, Han-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687624/
https://www.ncbi.nlm.nih.gov/pubmed/29179454
http://dx.doi.org/10.18632/oncotarget.19874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687624/
https://www.ncbi.nlm.nih.gov/pubmed/29179454
http://dx.doi.org/10.18632/oncotarget.19874

Ejemplares similares